Asset

Sufentanil

Talphera Inc. Common Stock

Revenue

No revenue reported in loaded filings.

Clinical trials (3)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT02662556phase3completed2016-03-012016-06-01Talphera, IncA Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain
NCT02356588phase3completed2015-02-012015-06-01Talphera, IncA Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal Surgery
NCT02447848phase3completed2015-10-012016-06-01Talphera, IncOpen-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain

FDA applications (0)

This company has no applications containing this asset.

Marketed products (0)